Hepatocellular Carcinoma   

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice? ...

Are there factors which would make you more likely to use atezo/bev vs durva/treme vs TKI?

Would portal hypertensive gastropathy or colopathy sway you away from using it?

Or offer resection followed by adjuvant therapy? 

Will the results of the recently published randomized comparison of proton beam therapy (PBT) vs. transarterial chemoembolization (TACE) change the wa...

What if actively on immunosuppression or with active lupus? For this case, presume the patient is not a candidate for resection or IR guided therapies...

Is there a difference in efficacy if dose is given later point during the course of therapy?

How do you sequence systemic treatment options for in patients with Child's Pugh B (or greater) in context of IMbrave150 and HIMALAYA? When do you in...

Previously untreated

The patient already received PLADO+sorafenib, Y90, and Atezolizumab/Bevacizumab complicated by recurrent episodes of bleeding from esophageal varices....

Would you offer liver transplant in the setting of metastatic disease? 

Would you try atezolizumab/bevacizumab or switch to a TKI?

For example in a patient with a history of PE?

i.e. EGD surveillance for varices?

What parameters do you use to decide to treat beyond progression? Is there any efficacy data from this specific study subgroup in IMbrave150?

ex. VEGFR2 expression, inflammatory signature, PDL1, etc.

Do you continue atezolizumab alone? Would you avoid anticoagulation?

In light of the SIRveNIB trial results and now IMbrave150, what is the role of intra-arterial therapy now?

Do you screen even asymptomatic patients?

Does the Child Pugh score factor in your treatment decision, i.e. Child Pugh score C?